J Yeo1, G Karimova, S Bansal. 1. Education Centre, Wansbeck General Hospital, Woodhorn Lane, Ashington, Northumberland NE63 9JJ, UK. jennyyeo@doctors.org.uk
Abstract
BACKGROUND: co-morbidity has been shown to be an important consideration in COPD with an estimated prevalence of 84%. In the Netherlands, a weak association between health-related quality of life and lung function has been found, with a closer link to co-morbidity. OBJECTIVE: to determine the influence of co-morbidity on quality of life and health service utilisation in older patients with COPD in the community. DESIGN: observational cohort study. SETTING: general practice in the North East of England that has a list size of 8300. PARTICIPANTS: 27 patients aged 70 years or above on the practice COPD register. MEASUREMENTS: data on age and sex, spirometry to confirm the diagnosis of COPD, questionnaires to assess quality of life, activities of daily living (ADLs) and co-morbidity. Health service utilisation was recorded by the number of primary and secondary care attendances in the previous year. RESULTS: 10 had mild, 12 had moderate, and 5 had severe disease. Mean age was 76 years. Quality of life (QOL), co-morbidity and health service utilisation measurements were not significantly different between COPD severity groups. There was a significant positive correlation between increasing co-morbidity and poor QOL (r = 0.45, P < 0.05), and significant negative correlation between co-morbidity and ADL scores (scored inversely), r = -0.54, P < 0.05. Significant negative correlation was found between co-morbidity and primary care attendances (r = -0.41, P < 0.05) and significant positive correlation between worsening QOL and secondary care attendances (r = 0.46, P < 0.05). CONCLUSIONS: co-morbidity has an important part to play in COPD assessment, more accurately reflecting QOL in our population. Health service utilisation did not correlate to forced expiratory volume (FEV1)-defined COPD severity.
BACKGROUND: co-morbidity has been shown to be an important consideration in COPD with an estimated prevalence of 84%. In the Netherlands, a weak association between health-related quality of life and lung function has been found, with a closer link to co-morbidity. OBJECTIVE: to determine the influence of co-morbidity on quality of life and health service utilisation in older patients with COPD in the community. DESIGN: observational cohort study. SETTING: general practice in the North East of England that has a list size of 8300. PARTICIPANTS: 27 patients aged 70 years or above on the practice COPD register. MEASUREMENTS: data on age and sex, spirometry to confirm the diagnosis of COPD, questionnaires to assess quality of life, activities of daily living (ADLs) and co-morbidity. Health service utilisation was recorded by the number of primary and secondary care attendances in the previous year. RESULTS: 10 had mild, 12 had moderate, and 5 had severe disease. Mean age was 76 years. Quality of life (QOL), co-morbidity and health service utilisation measurements were not significantly different between COPD severity groups. There was a significant positive correlation between increasing co-morbidity and poor QOL (r = 0.45, P < 0.05), and significant negative correlation between co-morbidity and ADL scores (scored inversely), r = -0.54, P < 0.05. Significant negative correlation was found between co-morbidity and primary care attendances (r = -0.41, P < 0.05) and significant positive correlation between worsening QOL and secondary care attendances (r = 0.46, P < 0.05). CONCLUSIONS: co-morbidity has an important part to play in COPD assessment, more accurately reflecting QOL in our population. Health service utilisation did not correlate to forced expiratory volume (FEV1)-defined COPD severity.
Authors: Ji Young Hong; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Ae Kang; Se Kyu Kim; Joon Chang; Young Sam Kim Journal: Qual Life Res Date: 2015-04-05 Impact factor: 4.147
Authors: Javier de Miguel-Díez; Pilar Carrasco-Garrido; Javier Rejas-Gutierrez; Antonio Martín-Centeno; Elena Gobartt-Vázquez; Valentín Hernandez-Barrera; Angel Gil de Miguel; Rodrigo Jimenez-Garcia Journal: BMC Cardiovasc Disord Date: 2010-02-18 Impact factor: 2.298
Authors: Debra E Irwin; Charles A Atwood; Ron D Hays; Karen Spritzer; Honghu Liu; James F Donohue; Nancy Kline Leidy; Susan E Yount; Darren A DeWalt Journal: Qual Life Res Date: 2014-10-12 Impact factor: 4.147
Authors: R Graham Barr; Bartolome R Celli; David M Mannino; Thomas Petty; Stephen I Rennard; Frank C Sciurba; James K Stoller; Byron M Thomashow; Gerard M Turino Journal: Am J Med Date: 2009-04 Impact factor: 4.965
Authors: John R Hurst; Mohd Kashif Siddiqui; Barinder Singh; Precil Varghese; Ulf Holmgren; Enrico de Nigris Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-05-10
Authors: Kerry Schnell; Carlos O Weiss; Todd Lee; Jerry A Krishnan; Bruce Leff; Jennifer L Wolff; Cynthia Boyd Journal: BMC Pulm Med Date: 2012-07-09 Impact factor: 3.317